Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Return on Capital Employed: 2018-2025

Historic Return on Capital Employed for Dianthus Therapeutics (DNTH) over the last 5 years, with Sep 2025 value amounting to -0.33%.

  • Dianthus Therapeutics' Return on Capital Employed fell 9.00% to -0.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.33%, marking a year-over-year decrease of 9.00%. This contributed to the annual value of -0.39% for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q3 2025, Dianthus Therapeutics' Return on Capital Employed stood at -0.33%, which was up 19.94% from -0.41% recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Return on Capital Employed registered a high of -0.19% during Q2 2024, and its lowest value of -0.58% during Q1 2023.
  • For the 3-year period, Dianthus Therapeutics' Return on Capital Employed averaged around -0.34%, with its median value being -0.33% (2025).
  • Per our database at Business Quant, Dianthus Therapeutics' Return on Capital Employed spiked by 37bps in 2024 and then declined by 22bps in 2025.
  • Over the past 4 years, Dianthus Therapeutics' Return on Capital Employed (Quarterly) stood at -0.50% in 2022, then rose by 22bps to -0.27% in 2023, then dropped by 2bps to -0.29% in 2024, then fell by 9bps to -0.33% in 2025.
  • Its Return on Capital Employed was -0.33% in Q3 2025, compared to -0.41% in Q2 2025 and -0.34% in Q1 2025.